<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> is a new thieno-<z:chebi fb="1" ids="16227">pyridine</z:chebi> derivative and has a more potent inhibitory effect on platelet aggregation, dependent on <z:chebi fb="13" ids="16761">ADP</z:chebi> rather than <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>In a phase I study performed in Japan, significant inhibition of <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced platelet aggregation and prolongation of <z:mp ids='MP_0001914'>bleeding</z:mp> time was observed in the dose range of 25, 50 and 75 mg </plain></SENT>
<SENT sid="2" pm="."><plain>These effects were comparable to 200 or 300 mg of <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Antithrombotic effects have also been shown in experimental animal models </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> is expected to reduce the incidence of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> since smaller doses are sufficient to suppress platelet aggregation compared to <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> has been proven to be a potent and well-tolerated antiplatelet agent for <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> patients at risk of <z:mp ids='MP_0005048'>thrombosis</z:mp>, in Europe </plain></SENT>
</text></document>